Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study

BACKGROUND: The aim of the study was to determine the efficacy and safety of triple therapy with a first-generation protease inhibitor (PI; boceprevir, telaprevir) plus peginterferon alfa-2a or -2b plus ribavirin, and dual therapy (peginterferon alfa-2a or -2b plus ribavirin) in patients with chroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangia, Alessandra, Foster, Graham R., Berg, Christoph P., Curescu, Manuela, Ledinghen, Victor De, Habersetzer, François, Manolakopoulos, Spilios, Negri, Elisa, Papatheodoridis, George, Ahlers, Silke, Castillo, Marco, Bakalos, Georgios, Mauss, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411384/
https://www.ncbi.nlm.nih.gov/pubmed/28469364
http://dx.doi.org/10.20524/aog.2017.0136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411384/
https://www.ncbi.nlm.nih.gov/pubmed/28469364
http://dx.doi.org/10.20524/aog.2017.0136

Ejemplares similares